These data prompted the current study to address on a functional level in mouse models whether inhibition of the CXCL16-CXCR6 pathway might be suitable to inhibit steatohepatitis and macrophage accumulation in NAFLD. This evidence concerns the gene CXCR6 and metabolic dysfunction-associated steatotic liver disease.